Cannabis Medical Research | The Kind Green

Cannabis Medical Research

This sec­tion of the site is a ded­i­cated news watch that com­piles news and infor­ma­tion on Cannabis Research from the most respected news sources.

Marijuana for Post Traumatic Stress Disorder Study

Cannabis Medical Research | 0 comments

MAPS is cur­rently seek­ing reg­u­la­tory approval to con­duct a study of smoked and/or vapor­ized mar­i­juana for symp­toms of PTSD in vet­er­ans of war. MAPS is cur­rently the only orga­ni­za­tion work­ing to demon­strate the safety and effi­cacy of botan­i­cal mar­i­juana as a pre­scrip­tion med­i­cine for spe­cific med­ical uses to the sat­is­fac­tion of the U.S. Food and Drug Administration. MAPS’ efforts to ini­ti­ate med­ical mar­i­juana research have been hin­dered by the National...

read more

A Double Blind, Active Placebo Controlled Crossover Trial of the Antinociceptive Effects of Smoked Marijuana on Subjects with Neuropathic Pain; Correlation with Changes in Mood, Cognition, and Psychomotor Performance

Cannabis Medical Research | 0 comments

Thirty-eight patients with cen­tral and periph­eral neu­ro­pathic pain under­went a stan­dard­ized pro­ce­dure for smok­ing either high-dose (7%), low-dose (3.5%) or placebo cannabis. In addi­tion to the pri­mary out­come of pain inten­sity, sec­ondary out­come mea­sures included evoked pain using heat-pain thresh­old, sen­si­tiv­ity to light touch, psy­choac­tive side-effects, and neu­ropsy­cho­log­i­cal per­for­mance. A mixed lin­ear model demon­strated an anal­gesic response to smok­ing cannabis....

read more

Analgesic Efficacy of Smoked Cannabis

Cannabis Medical Research | 0 comments

In a ran­dom­ized, double-blinded, placebo con­trolled, crossover trial in fif­teen healthy vol­un­teers, we eval­u­ated the effects of low, medium, and high dose smoked cannabis (respec­tively 2%, 4%, and 8% 9-delta-tetrahydrocannibinol by weight) on pain and cuta­neous hyper­al­ge­sia induced by intra­der­mal cap­saicin. Cap­saicin was injected into oppo­site fore­arms 5 and 45 min­utes after drug expo­sure and pain, hyper­al­ge­sia, tetrahy­dro­can­nib­i­nol plasma lev­els, and side effects...

read more

Effects of Medicinal Cannabis on CD4 immunity in AIDS

Cannabis Medical Research | 0 comments

Mul­ti­ple sci­en­tific reviews have con­cluded that although some research reports immuno­sup­pres­sive con­se­quences of cannabis, addi­tional research which includes cost/benefit approach and effects of ther­a­peu­tic doses on spe­cific immune responses is needed to eval­u­ate cannabis as an agent to treat pain, reduce nau­sea and wast­ing in patients with severe dis­ease such as AIDS and can­cers. Anes­thetic reagents are gen­er­ally immuno­sup­pres­sive for CD4 T-cell activ­ity, which would impact...

read more

Effects of Cannabis Therapy on Endogenous Cannabinoids

Cannabis Medical Research | 0 comments

This study assessed the effect of acute and chronic treat­ment of rats with the cannabi­noid ago­nist, WIN-55212–2, on the lev­els of anan­damide in blood and brain tis­sue. No change was observed in plasma anan­damide con­cen­tra­tion after either acute or chronic treat­ment. Like­wise, there was no sig­nif­i­cant change in anan­damide lev­els in three brain regions: cere­bel­lum, nucleus accum­bens, and brain­stem. Chronic, but not acute, treat­ment with WIN-55212–2 caused a marked increase in anan­damide...

read more

Mechanisms of Cannabinoid Analgesia

Cannabis Medical Research | 0 comments

The full results of this study were pub­lished in PAIN Below is a brief sum­mary of these results. Anec­do­tal evi­dence sug­gests that cannabi­noid drugs, which include the main active ingre­di­ent of mar­i­juana delta-9-tetrahydrocannabinol, may be use­ful for the treat­ment of trigem­i­nal pain syn­dromes, includ­ing headache. These stud­ies exam­ined the effect of one cannabi­noid drug, WIN 55,212–2, on the trans­mis­sion of pain sig­nals involved in head pain. The activ­ity of pain trans­mis­sion...

read more

Impact of Repeated Cannabis Treatments on Driving Abilities

Cannabis Medical Research | 0 comments

A sig­nif­i­cant con­cern in uti­liz­ing cannabis, a known psy­choac­tive drug, in the treat­ment of med­ical con­di­tions is the poten­tial for neg­a­tive cog­ni­tive side effects. Dri­ving is a com­plex activ­ity requir­ing numer­ous cog­ni­tive abil­i­ties, includ­ing con­tin­u­ous track­ing, sequen­tial move­ments, judg­ment, plan­ning, per­cep­tion, atten­tion and speeded infor­ma­tion pro­cess­ing. Pre­vi­ous stud­ies have demon­strated that a sin­gle dose of mar­i­juana results...

read more

Placebo-controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy

Cannabis Medical Research | 0 comments

Of 127 vol­un­teers screened, 34 eli­gi­ble sub­jects enrolled and 28 com­pleted both cannabis and placebo treat­ments. Among com­pleters, pain relief was greater with cannabis than placebo (median dif­fer­ence in DDS pain inten­sity change, 3.3 points, effect size = 0.60; p = 0.016). The pro­por­tions of sub­jects achiev­ing at least 30% pain relief with cannabis ver­sus placebo were 0.46 [95% CI 0.28, 0.65] and 0.18 [0.03, 0.32]. Mood and daily func­tion­ing improved to a sim­i­lar extent dur­ing both treat­ment...

read more

Sleep and Medicinal Cannabis

Cannabis Medical Research | 0 comments

Recently, there has been renewed sci­en­tific inter­est in exam­in­ing the med­ical effi­cacy of cannabis in spe­cific patient pop­u­la­tions. For, exam­ple, both the Insti­tute of Med­i­cine and the NIH recently reported med­i­c­i­nal cannabis might be use­ful in the treat­ment of pain in HIV+ patients. HIV+ patients expe­ri­ence a num­ber of clin­i­cal seque­lae to the infec­tion, even when they are oth­er­wise con­sid­ered clin­i­cally “asymp­to­matic.” Per­haps one of the ear­li­est...

read more

Short-Term Effects of Cannabis Therapy on Spasticity in MS

Cannabis Medical Research | 0 comments

Mul­ti­ple Scle­ro­sis (MS) is the most com­mon debil­i­tat­ing neu­ro­logic dis­ease of young peo­ple, affect­ing at least 250,000 per­sons in the US, often between the ages of 20 and 40. Symp­tom man­i­fes­ta­tion varies con­sid­er­ably from per­son to per­son; how­ever, one fre­quently noted con­comi­tant is spas­tic­ity, which causes pain, spasms, loss of func­tion and dif­fi­cul­ties in nurs­ing care. The present appli­ca­tion is designed to explore the short-term effec­tive­ness and safety of...

read more